MICHELLE MILES: Open Payments
NPI 1992488878 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$871 in 31 payments from 22 companies in 2025. Trend: 2023 $32 · 2024 $544 · 2025 $871
Food & beverage: $871
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $264 |
| Novo Nordisk Inc | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| PFIZER INC. | 2 | $37 |
| Exact Sciences Corporation | 1 | $33 |
| ABBVIE INC. | 1 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
Products named: REPATHA, AUSTEDO XR, REXULTI, NURTEC ODT, Ozempic, Cologuard Collection Kit, UBRELVY, LEQVIO.
Industry payments across ID — which companies pay providers there.
